Your browser doesn't support javascript.
loading
Surgical Management of Metastatic Adrenocortical Carcinoma.
Passman, Jesse E; Amjad, Wajid; Ginzberg, Sara P; Soegaard Ballester, Jacqueline M; Finn, Caitlin; Wachtel, Heather.
Afiliação
  • Passman JE; Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Amjad W; Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Ginzberg SP; Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Soegaard Ballester JM; Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Finn C; Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA.
  • Wachtel H; Department of Surgery, University of Pennsylvania Health System, Philadelphia, PA.
World J Surg ; 48(1): 110-120, 2024 01.
Article em En | MEDLINE | ID: mdl-38463201
ABSTRACT

Introduction:

Adrenocortical carcinoma (ACC) is a notoriously aggressive cancer with a dismal prognosis, especially for patients with metastatic disease. Metastatic ACC is classically a contraindication to operative management. Here, we evaluate the impact of primary tumor resection and metastasectomy on survival in metastatic ACC.

Methods:

We performed a retrospective cohort study of patients with metastatic ACC (2010-2019) utilizing the National Cancer Database. The primary outcome was overall survival (OS). Cox proportional hazards models were developed to evaluate the associations between surgical management and survival. Propensity score matching (PSM) was utilized to account for selection bias in receipt of surgery.

Results:

Of 976 subjects with metastatic ACC, 38% underwent surgical management. Median OS across all patients was 7.6 months. On multivariable Cox proportional hazards regression, primary tumor resection alone (HR 0.523; p<0.001) and primary resection with metastasectomy (HR 0.372; p<0.001) were significantly associated with improved OS. Metastasectomy alone had no association with OS (HR 0.909; p=0.740). Primary resection with metastasectomy was associated with improved OS over resection of the primary tumor alone (HR 0.636; p=0.018). After PSM, resection of the primary tumor alone remained associated with improved OS (HR 0.593; p<0.001), and metastasectomy alone had no survival benefit (HR 0.709; p=0.196) compared with non-operative management; combined resection was associated with improved OS over primary tumor resection alone (HR 0.575, p=0.008).

Conclusion:

In metastatic ACC, patients may benefit from primary tumor resection alone or in combination with metastasectomy, however further research is required to facilitate appropriate patient selection.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Córtex Suprarrenal / Carcinoma Adrenocortical / Metastasectomia Limite: Humans Idioma: En Revista: World J Surg Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Panamá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias do Córtex Suprarrenal / Carcinoma Adrenocortical / Metastasectomia Limite: Humans Idioma: En Revista: World J Surg Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Panamá